January 3, 2024 03:30 PM ESTUpdated January 16, 06:11 AM
FDA+

All the new drugs ap­proved in 2023: Alzheimer's and gene ther­a­py cap a five-year high

ENDPOINTS

Af­ter kick­ing off 2023 with a po­ten­tial megablock­buster in Ei­sai and Bio­gen’s new Alzheimer’s drug Leqem­bi, in to­tal­i­ty the FDA signed off on 10 more …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times